Investor Centre

Pharmaceutical research company Pharmaxis today announced it has completed recruitment of its international clinical trial evaluating Bronchitol® (mannitol) in adults with cystic fibrosis. The results of the trial (CF303) are expected to be reported in the second quarter of 2017.

The Phase 3 trial is being conducted in accordance with the requirements of the US Food and Drug Administration (FDA) to gain approval for Bronchitol to treat cystic fibrosis (CF) in the United States in adult patients. Subject to a positive trial outcome, the Company will submit a response to the FDA and a decision on approval can be expected in 2018.

Valuable Development Pipeline with the Funds to Exploit

Summary of Pharmaxis business, risks and catalysts at June 2016

Pharmaxis was pleased to host the CEO of Cystic Fibrosis Australia (CFA) Nettie Burke at the company headquarters for a meeting with staff and a tour of our research laboratories and manufacturing facilities.

Pharmaxis developed Bronchitol for the treatment of cystic fibrosis patients and Ms Burke was keen to discuss the clinical development and local manufacturing of the product.

Another area of mutual interest is the fact that the Pharmaxis drug discovery team is investigating potential new therapies for fibrotic diseases.

Ms Burke addressed staff and some members of the board at a morning tea to explain more about the work of CFA.

Pharmaxis staff have initiated fundraising and collected more than $2,000 in the last twelve months to support Cystic Fibrosis Australia – funds which will be used to help people with CF and their families.

Picture: Cystic Fibrosis Australia CEO Nettie Burke with Pharmaxis CEO Gary Phillips and members of the drug discovery team.